AirDuo Digihaler
Total Payments
$1.2M
Transactions
22,096
Doctors
8,675
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $41,232 | 7 | 4 |
| 2023 | $26,968 | 977 | 864 |
| 2022 | $669,295 | 7,543 | 3,524 |
| 2021 | $352,989 | 12,597 | 5,956 |
| 2020 | $154,625 | 972 | 646 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $740,679 | 45 | 59.5% |
| Food and Beverage | $346,630 | 21,989 | 27.8% |
| Consulting Fee | $138,947 | 23 | 11.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,222 | 27 | 1.1% |
| Travel and Lodging | $3,131 | 11 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $2,500 | 1 | 0.2% |
Payments by Type
Research
$740,679
45 transactions
General
$504,431
22,051 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma | Teva Pharmaceuticals USA, Inc. | $685,093 | 0 |
| Use of ProAir Digihaler in COPD - Characterization of inhalation parameters from a cohort of patient at-risk for AECOPD in an outpatient setting | Teva Pharmaceuticals USA, Inc. | $14,556 | 0 |
| Use of ProAir Digihaler in COPD - Characterization of inhalation metrics from a cohort of patient at-risk for AECOPD in an outpatient setting | Teva Pharmaceuticals USA, Inc. | $13,225 | 0 |
| ProAir Digihaler in COPD Disease Management: A real world study to assess ProAir Digihaler inhalation parameters thresholds and their use to identify deterioration in clinical practice | Teva Pharmaceuticals USA, Inc. | $11,739 | 0 |
| CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma | Teva Pharmaceuticals USA, Inc. | $7,692 | 0 |
| Publications Support | Teva Pharmaceuticals USA, Inc. | $6,414 | 4 |
| US expert consensus on short-acting beta-agonist reliever medication use for asthma clinical decision-making: a mixed-method Delphi adjudication approach | Teva Pharmaceuticals USA, Inc. | $1,306 | 1 |
| Expert consensus on SABA use for asthma clinical decision-making: a Delphi approach | Teva Pharmaceuticals USA, Inc. | $653.19 | 1 |
Top Doctors Receiving Payments for AirDuo Digihaler
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Elizabeth Rau | — | Royal Oak, MI | $734,940 | 47 |
| , MD | Pulmonary Disease | Houston, TX | $16,375 | 2 |
| , M.D | Pulmonary Disease | Lebanon, NH | $16,199 | 4 |
| , MD | Internal Medicine | Ann Arbor, MI | $15,918 | 5 |
| , MD | Pulmonary Disease | San Antonio, TX | $15,918 | 5 |
| , M.D | Allergy & Immunology | Fishers, IN | $14,873 | 27 |
| , M.D | Allergy & Immunology | Woodland, CA | $13,789 | 3 |
| Mark Dransfield | Critical Care Medicine | Birmingham, AL | $13,625 | 2 |
| , M.D., MSC | Internal Medicine | Denver, CO | $13,625 | 2 |
| , M.D | Critical Care Medicine | Ann Arbor, MI | $12,853 | 8 |
| , MD | Critical Care Medicine | Kansas City, KS | $7,807 | 7 |
| , M.D | Specialist | Stockton, CA | $6,189 | 9 |
| , M.D | Internal Medicine | Baltimore, MD | $5,000 | 2 |
| , M.D | Allergy | Montgomery, AL | $4,616 | 57 |
| , MD | Allergy & Immunology | Charlotte, NC | $2,353 | 60 |
| , MD | Allergy | Summit, NJ | $2,105 | 6 |
| , MD | Critical Care Medicine | New York, NY | $2,025 | 2 |
| , MD | Internal Medicine | Ann Arbor, MI | $1,111 | 8 |
| , MD | Pediatric Allergy/Immunology | Kansas City, MO | $1,000 | 3 |
| , MD | Allergy & Immunology | Chicago, IL | $758.68 | 37 |
| , MD | Internal Medicine | Louisville, KY | $650.02 | 72 |
| , M.D., | Allergy | Saint Charles, IL | $625.03 | 26 |
| , MD | Internal Medicine | Houston, TX | $585.46 | 27 |
| , PA-C | Physician Assistant | New York, NY | $543.66 | 24 |
| , PA | Medical | Tarentum, PA | $532.88 | 56 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 8,675
- Transactions 22,096
About AirDuo Digihaler
AirDuo Digihaler is a drug associated with $1.2M in payments to 8,675 healthcare providers, recorded across 22,096 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2020 to 2024. In 2024, $41,232 was paid across 7 transactions to 4 doctors.
The most common payment nature for AirDuo Digihaler is "Unspecified" ($740,679, 59.5% of total).
AirDuo Digihaler is associated with 8 research studies, including "Utilizing Advances in Digital Inhaler Technology to Understand Heterogeneous Treatment Responses to Biologics in Severe Asthma" ($685,093).